Usana Health Sciences analyst ratings
Usana Health Sciences analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/28/2022 | -18.03% | DA Davidson | $58 → $57 | Maintains | Neutral |
| 07/12/2022 | -16.59% | DA Davidson | $76 → $58 | Maintains | Neutral |
| 07/07/2022 | -23.78% | Jefferies | $78 → $53 | Downgrades | Hold → Underperform |
| 04/27/2022 | 9.29% | DA Davidson | $86 → $76 | Maintains | Neutral |
| 04/14/2022 | 23.67% | DA Davidson | → $86 | Initiates Coverage On | → Neutral |
| 02/10/2021 | 81.19% | Roth Capital | $107 → $126 | Maintains | Buy |
| 12/17/2020 | 53.87% | Roth Capital | → $107 | Initiates Coverage On | → Buy |
| 08/22/2019 | -6.53% | Jefferies | → $65 | Initiates Coverage On | → Hold |
| 07/03/2019 | 0.66% | Sidoti & Co. | $108 → $70 | Downgrades | Buy → Neutral |
| 04/16/2019 | — | Tigress Financial | Initiates Coverage On | → Buy | |
| 04/23/2018 | — | Pivotal Research | Downgrades | Buy → Hold | |
| 01/24/2018 | — | Sidoti & Co. | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析師公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/28/2022 | -18.03% | DA Davidson | 58 美元 → 57 美元 | 維護 | 中立 |
| 2022 年 12 月 7 日 | -16.59% | DA Davidson | 76 美元 → 58 美元 | 維護 | 中立 |
| 07/07/2022 | -23.78% | 傑富瑞集團 | 78 美元 → 53 美元 | 降級 | 持有 → 表現不佳 |
| 04/27/2022 | 9.29% | DA Davidson | 86 美元 → 76 美元 | 維護 | 中立 |
| 2022 年 4 月 14 日 | 23.67% | DA Davidson | → 86 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2021 年 10 月 2 日 | 81.19% | 羅斯資本 | 107 美元 → 126 美元 | 維護 | 買 |
| 2020 年 12 月 17 日 | 53.87% | 羅斯資本 | → 107 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/22/2019 | -6.53% | 傑富瑞集團 | → 65 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 07/03/2019 | 0.66% | Sidoti & Co. | 108 美元 → 70 美元 | 降級 | 買入 → 中性 |
| 04/16/2019 | — | 泰格雷斯金融 | 啓動覆蓋範圍開啓 | → 購買 | |
| 04/23/2018 | — | 關鍵研究 | 降級 | 買入 → 持有 | |
| 2018 年 1 月 24 日 | — | Sidoti & Co. | 降級 | 買入 → 中性 |
Usana Health Sciences Questions & Answers
Usana 健康科學問題與解答
The latest price target for Usana Health Sciences (NYSE: USNA) was reported by DA Davidson on July 28, 2022. The analyst firm set a price target for $57.00 expecting USNA to fall to within 12 months (a possible -18.03% downside). 5 analyst firms have reported ratings in the last year.
戴維森於2022年7月28日公佈了Usana Health Sciences（紐約證券交易所代碼：USNA）的最新目標股價。該分析公司將目標股價定爲57.00美元，預計USNA將在12個月內降至-18.03％（可能下跌18.03％）。去年有5家分析公司公佈了評級。
The latest analyst rating for Usana Health Sciences (NYSE: USNA) was provided by DA Davidson, and Usana Health Sciences maintained their neutral rating.
Usana Health Sciences（紐約證券交易所代碼：USNA）的最新分析師評級由DA Davidson提供，Usana Health Sciences維持中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Usana Health Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Usana Health Sciences was filed on July 28, 2022 so you should expect the next rating to be made available sometime around July 28, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Usana Health Sciences的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Usana Health Sciences的最新評級是在2022年7月28日公佈的，因此您應該預計下一個評級將在2023年7月28日左右公佈。
While ratings are subjective and will change, the latest Usana Health Sciences (USNA) rating was a maintained with a price target of $58.00 to $57.00. The current price Usana Health Sciences (USNA) is trading at is $69.54, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Usana Health Sciences（USNA）評級維持不變，目標股價爲58.00美元至57.00美元。Usana Health Sciences（USNA）目前的交易價格爲69.54美元，超出了分析師的預期區間。